"Dwyer, M. G." . "Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years" . "Zivadinov, Robert" . . . "Hussein, S." . . "Seidl, Zden\u011Bk" . . . "10" . . "34" . "73793" . "Potts, J. A" . . . "RIV/00064165:_____/13:10193029!RIV14-MZ0-00064165" . . "Dole\u017Eal, Ond\u0159ej" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "Bergsland, N." . "Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years"@en . "Kr\u00E1sensk\u00FD, Jan" . . "Hor\u00E1kov\u00E1, Dana" . "thalamus; neuroimaging; multiple sclerosis; male; major clinical study; lateral brain ventricle; human; gray matter; female; disease duration; disability; controlled study; brain size; brain cortex; brain atrophy; Adult"@en . "Kalin\u010D\u00EDk, Tom\u00E1\u0161" . . "American Journal of Neuroradiology" . . . "Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years" . "RIV/00064165:_____/13:10193029" . . "Havrdov\u00E1, Eva" . . "Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years"@en . . "10.3174/ajnr.A3503" . "9"^^ . "7"^^ . . . . . "http://dx.doi.org/10.3174/ajnr.A3503" . . . . "12"^^ . "[02546A9FD379]" . . . "Van\u011B\u010Dkov\u00E1, Manuela" . . . "BACKGROUND AND PURPOSE: Pathologic changes inGMhave an important role in MS.Weinvestigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P<.001), thalamus (P=.006), and total SDGM (P=.0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years."@en . . . . . . "BACKGROUND AND PURPOSE: Pathologic changes inGMhave an important role in MS.Weinvestigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P<.001), thalamus (P=.006), and total SDGM (P=.0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years." . . . . "0195-6108" . . "000330539400016" . . "I, P(NT13237), Z(MSM0021620849)" . .